Celltrion, Inc.
068270
Hisse Senetlerindeki Sıralama
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Hisse Fiyatı
$146.63
Piyasa Değeri
$33.44B
Değişim (1 gün)
-1.52%
Değişim (1 yıl)
23.60%
Ülke
KR
Ticaret Celltrion, Inc. (068270)
Kategori
Healthcare
Celltrion, Inc. (068270) için gelir
Jun 2026 itibarıyla gelir TTM: $3.69B
Celltrion, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $3.69B'dir. 2024 yılında şirketin geliri $2.42B önceki yıla göre artış 2023 yılındaki $1.68B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Celltrion, Inc. için 2007 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $3.69B | 28.08% |
| 2025 | $2.88B | 19.08% |
| 2024 | $2.42B | 43.92% |
| 2023 | $1.68B | -7.11% |
| 2022 | $1.81B | 13.65% |
| 2021 | $1.59B | -6.50% |
| 2020 | $1.70B | 74.29% |
| 2019 | $977.23M | 10.80% |
| 2018 | $881.97M | -0.96% |
| 2017 | $890.53M | 60.12% |
| 2016 | $556.15M | 8.32% |
| 2015 | $513.45M | 19.28% |
| 2014 | $430.46M | 100.34% |
| 2013 | $214.86M | -34.69% |
| 2012 | $328.97M | 36.64% |
| 2011 | $240.76M | 49.20% |
| 2010 | $161.36M | 28.65% |
| 2009 | $125.42M | 93.41% |
| 2008 | $64.85M | 1.02% |
| 2007 | $64.19M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| $12.62B | 242.09% |
US
|
|
| $2.23B | -39.63% |
US
|
|
| $15.74B | 326.63% |
AU
|
|
| $9.57B | 159.39% |
BE
|
|
| $6.02B | 63.16% |
NL
|
